On Oct. 24, the Cardio-Renal Advisory Committee also will look at results of the 21-month Prospective Randomized Milrinone (BRACKET)Sterling's Primacor(BRACKET) Survival Evaluation (PROMISE). Interim results of the trial, which was completed in September 1990, caused Sterling to discontinue development of its phosphodiesterase III inhibitor. On Oct. 25, the committee will discuss antihypertensive drug development. The meeting is scheduled for Jack Masur Auditorium on the NIH campus from 9 a.m.- 5 p.m. each day. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth